Andy Leake’s Post

🌟 Is Your Influenza Clinical Trial Ready for Flu Season? 🌟 Flu season is fast approaching, bringing unique challenges to respiratory clinical trials. Is your study prepared to recruit and retain patients effectively? In our latest blog, "Key Considerations for Patient Recruitment and Retention - Part #1," we explore essential strategies to ensure your trial stands out. 🔍 Highlights: ⭐️Patient Awareness: Learn how to increase trial visibility and engage the local community. ⭐️Community Outreach: Discover effective methods to reach potential participants. ⭐️Referral Networks: Optimize your network to maximize patient recruitment. 🚀 Boost Your Recruitment Success! Join us as we delve into Innovative Trials' proven strategies that have led to a 297% increase in patient randomization rates. Don’t miss out on practical tips and expert insights to prepare your trial for the upcoming flu season. 📞 Special Offer: Book a free 30-minute strategy call with our CEO, Kate Shaw, to get personalized advice on making your influenza study a success Read the full blog now and get ahead this flu season!👉 https://bit.ly/3WVnVEm #ClinicalTrials #PatientEngagement #InnovativeSolutions #ClinicalResearch #PharmaExcellence #InfluenzaStudy #Covid19 #InnovativeTrials #FluStudy #EffectiveSupport #patientrecruitment #pharma #pharmaceutical #pharmaceuticals #pharmaindustry #pharmaceuticalindustry #patientaccess #bootsontheground #communityengagement

🌟 Is Your Influenza Clinical Trial Ready for Flu Season? 🌟 Is your study prepared to recruit and retain patients effectively? In our, "Key Considerations for Patient Recruitment and Retention - Part #1," we explore essential strategies to ensure your trial stands out. 🔍 Highlights: ⭐️Patient Awareness: Learn how to increase trial visibility and engage the local community. ⭐️Community Outreach: Discover effective methods to reach potential participants. ⭐️Referral Networks: Optimize your network to maximize patient recruitment. 🚀 Boost Your Recruitment Success! Join us as we delve into Innovative Trials' proven strategies that have led to a 297% increase in patient randomization rates. Don’t miss out on practical tips and expert insights to prepare your trial for the upcoming flu season. 📞 Special Offer: Book a free 30-minute strategy call with our CEO, Kate Shaw, to get personalized advice on making your influenza study a success Read the full blog now and get ahead this flu season!👉 https://bit.ly/3WVnVEm #ClinicalTrials #PatientEngagement #InnovativeSolutions #ClinicalResearch #PharmaExcellence #InfluenzaStudy #Covid19 #InnovativeTrials #FluStudy #EffectiveSupport #patientrecruitment #pharma #pharmaceutical #pharmaceuticals #pharmaindustry #pharmaceuticalindustry #patientaccess #bootsontheground #communityengagement

Flu season is fast approaching - Are you ready?? Come and join our webinar focusing on all of the tips that could help your study. #patientrecruitment #patientretention #influenzastudy

Join Our Live Webinar on Influenza Studies! 📣 Title: Optimizing Patient Recruitment & Retention in Influenza Studies: Practical Strategies for Success 📅 Date: Wednesday, 4th September 🕒 Time: 3:00pm BST | 10:00am EST 🔗 https://bit.ly/4fGFxv5 As flu season approaches, the window for recruiting participants in influenza and vaccine studies is short and challenging. Learn how to optimize your patient recruitment and retention strategies with insights from industry experts at Innovative Trials, Parexel, ENTRADA, A Patient Experience Organization (PXO), and TransPerfect Life Sciences. Webinar Highlights: ⭐️Recruitment challenges in flu studies ⭐️Practical strategies for overcoming them ⭐️Real-world examples and case studies ⭐️Live Q&A session for personalized advice This session is crucial for clinical trial leads, patient recruiters, and anyone involved in influenza studies.  Don’t miss out—reserve your spot today 👉 https://bit.ly/4fGFxv5 #ClinicalTrials #PatientEngagement #ClinicalResearch #PharmaExcellence #InfluenzaStudy #Covid19 #InnovativeTrials #FluStudy #patientrecruitment #pharma #pharmaceutical #pharmaceuticals #pharmaindustry #pharmaceuticalindustry #patientaccess #bootsontheground #communityengagement Leanne Woehlke, Antonio Drea, Amber McAllister, Georgia Hardy

Thoughts on this? >> Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #biotech #pharma

Thoughts on this? >> Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

🔍NEW RESEARCH: Uncontrolled severe asthma is a type of asthma that doesn’t respond well to inhaled medicines alone, requiring specialist assessment. In Canada, oral corticosteroids (OCS) have traditionally been used alongside inhaled medications to manage severe asthma. However, OCS are associated with serious short- and long-term adverse effects, even at low doses. New treatment options, like injectable biologics, have shown promise in reducing OCS use and improving outcomes for patients with uncontrolled severe asthma. A recent study by GSK, in collaboration with Asthma Canada, revealed that 72% of people with uncontrolled severe asthma had substantial OCS use, highlighting the need for better treatment approaches. Read more: https://lnkd.in/dEYTj_dn #SevereAsthma #OCS #Biologics #Healthcare #Research

Demyelinating Polyneuropathy Treatment Takeda’s HyQvia Granted Approval by FDA Takeda's HyQvia has been approved by the FDA as a maintenance therapy for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). HyQvia is the only subcutaneous immune globulin infusion administered monthly and was initially approved for primary immunodeficiency in 2014. The FDA's approval is based on data from clinical trials showing a significant difference in relapse rates between patients treated with HyQvia and those receiving a placebo, as well as a tolerable safety profile. The approval of HyQvia offers an alternative subcutaneous option to intravenous immunoglobulin infusions, potentially addressing challenges for some patients and caregivers. This approval represents a pivotal moment in the treatment of CIDP and is expected to enhance the quality of life for many patients. For more details please click the link! https://lnkd.in/daZrc6jx #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

🌐 Exciting news in the #PharmaIndustry! The FDA has approved a groundbreaking new indication for #Wegovy (#semaglutide) injection, reducing the risk of #cardiovascular death, #heartattack, and #stroke in adults with cardiovascular disease and either #obesity or #overweight. 🎓 I personally conducted a research on this topic and developed this Python ASCVD Calculator tailoured for Diabetes Patients: https://shorturl.at/TVY58 💭Check it out and tell me what you think in the comment below. This marks a significant advancement in public health, addressing a critical need in a population with heightened cardiovascular risk. 📊 The efficacy and safety of Wegovy were rigorously evaluated in a multi-national, placebo-controlled trial, demonstrating a significant reduction in major adverse cardiovascular events compared to placebo. ⚠️ It's important to note the boxed warning regarding the risk of thyroid C-cell tumors and other potential side effects outlined in the prescribing information. 👩⚕️ Healthcare professionals and patients alike should carefully consider the benefits and risks of Wegovy in consultation with their healthcare provider. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #pharma #pharmaceutical #europe #pharmaceuticalindustry #healthcare #fda #ema #USA #biotech #pharmacy #drugdevelopment #qa #ra

EU committee recommends approval of AstraZeneca’s 𝗙𝗮𝘀𝗲𝗻𝗿𝗮 to treat eosinophilic granulomatosis with polyangiitis AstraZeneca's 𝗙𝗮𝘀𝗲𝗻𝗿𝗮 (𝗯𝗲𝗻𝗿𝗮𝗹𝗶𝘇𝘂𝗺𝗮𝗯) has been recommended for approval in the Europian Union as a treatment for patients with relapsing or refractory 𝗲𝗼𝘀𝗶𝗻𝗼𝗽𝗵𝗶𝗹𝗶𝗰 𝗴𝗿𝗮𝗻𝘂𝗹𝗼𝗺𝗮𝘁𝗼𝘀𝗶𝘀 𝘄𝗶𝘁𝗵 𝗽𝗼𝗹𝘆𝗮𝗻𝗴𝗶𝗶𝘁𝗶𝘀 (𝗘𝗚𝗣𝗔), a rare and potentially fatal condition. The 𝗖𝗛𝗠𝗣 recommended Fasenra for approval based on positive results from the MANDARA trial, which compared its effectiveness and safety to mepolizumab, the only approved treatment for EGPA. 𝗠𝗔𝗡𝗗𝗔𝗥𝗔 - It was a phase III trial that compared Fasenra to mepolizumab in patients with EGPA. 𝟭𝟰𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 were randomly assigned to receive either Fasenra or mepolizumab. 𝗥𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝗱: 60% of patients treated with Fasenra achieved remission, similar to those treated with mepolizumab. 𝗥𝗲𝘀𝘂𝗹𝘁𝘀: 41% of patients were able to completely stop taking oral corticosteroids, compared to 26% in the comparator group. People living with EGPA often face debilitating symptoms and suffer side effects from treatment with long-term oral corticosteroids. Follow Innovate Research for daily pharma/healthcare updates. #IndianPharma #RegulatoryReadiness #QualityManagemen #Pharmaceuticals #FDACompliance #PharmaInnovation #innovateresearch #ManufacturingExcellence #DigitalTransformation #OperationalEfficiency #HealthcareQuality #PharmaIndustry #SupplyChainVisibility #ContinuousImprovement